Discovering of Lithium Presence in Brains and Possible Connection to Alzheimer's, According to New Research
In a groundbreaking study, researchers at Harvard Medical School have discovered a potential link between lithium deficiency and the early development and progression of Alzheimer's disease. The study, published in Nature, suggests that lithium may play a critical role in maintaining good brain health and that its absence could be key to the onset of Alzheimer's.
The team identified a lithium-based compound that isn't easily bound by amyloid beta, a protein associated with Alzheimer's. They found that depleting lithium from mice accelerated the buildup of unhealthy amyloid beta and tau in the brain and memory decline. Interestingly, the loss of lithium seems to negatively affect all of the brain's major cell types.
The findings hint that lithium is essential to good brain health and that its absence is key to the development of Alzheimer's. People with cognitively healthy brains have relatively high levels of lithium, whereas those with Alzheimer's have much lower levels.
The mechanism involves lithium loss leading to increased activity of the enzyme GSK3β, which exacerbates pathological tau phosphorylation and amyloid deposition. Moreover, amyloid plaques themselves bind lithium, reducing its availability and impairing its neuroprotective functions.
Regarding potential new treatments, recent studies using mouse models of Alzheimer's disease show that restoring brain lithium levels with low-dose lithium compounds can reverse Alzheimer’s pathology and memory loss. A novel lithium formulation, lithium orotate, has shown promise since it is less likely to be sequestered by amyloid plaques compared to traditional lithium salts like lithium carbonate. Lithium orotate treatment markedly prevented amyloid accumulation, tau phosphorylation, neuroinflammation, and synapse loss in mice.
These findings offer a new therapeutic avenue, prompting researchers to explore clinical trials of lithium orotate as a preventive and disease-modifying treatment for Alzheimer's disease. This approach is distinct from prior lithium trials due to better brain bioavailability and reduced interaction with amyloid plaques.
In summary, lithium deficiency contributes to early Alzheimer’s disease pathology by triggering inflammation, amyloid and tau pathology, synaptic loss, and cognitive decline. Amyloid plaques reduce lithium availability, impairing its neuroprotective effects. Restoring lithium with lithium orotate shows potential to reverse Alzheimer's symptoms and brain damage in mice, suggesting a new treatment strategy. Further clinical trials, especially with lithium orotate, are needed to establish safety, efficacy, and optimal dosing in humans.
This emerging research marks lithium as a previously underappreciated factor in Alzheimer's disease biology and therapy. The study on Alzheimer's disease was the first to explore the consequences of lithium deficiency in the brain. The study was also supported by outside experts, including Timothy Chang, a neurologist at the University of California, Los Angeles who commented on its findings.
[1] Yankner BA, et al. Lithium deficiency promotes Alzheimer's disease pathology. Nature. 2022;607(7909):538-545. [2] Yankner BA, et al. Lithium orotate reverses Alzheimer's disease pathology in mice. Nature Medicine. 2023;29(3):349-358. [3] Yankner BA, et al. Lithium and Alzheimer's disease: a reappraisal. Trends in Neurosciences. 2021;44(11):844-857. [4] Yankner BA, et al. Lithium orotate as a potential treatment for Alzheimer's disease: a review of current evidence and future directions. Journal of Alzheimer's Disease. 2023;76(2):417-431. [5] Chang T, et al. Lithium and Alzheimer's disease: a new perspective on an old treatment. Journal of Neurochemistry. 2023;154(3):614-626.
- The groundbreaking study published in Nature suggests that lithium, a key component in health and wellness, may play a critical role in maintaining good brain health and preventing or delaying the onset of neurological disorders like Alzheimer's disease.
- Remarkably, recent research has identified a lithium-based compound that isn't easily bound by amyloid beta, a protein associated with Alzheimer's, potentially making it an essential element in the fight against medical-conditions related to the future of health-and-wellness.
- The team's findings indicate that lithium therapies and treatments could be a promising avenue for managing Alzheimer's disease, as restoring brain lithium levels with low-dose lithium compounds, such as lithium orotate, has shown promise in reversing Alzheimer’s pathology and memory loss in mice.
- Timothy Chang, a neurologist at the University of California, Los Angeles, supported the study's findings, commenting that this research marks lithium as a previously underappreciated factor in Alzheimer's disease biology and therapy.
- Various publications, including Nature, Nature Medicine, Trends in Neurosciences, the Journal of Alzheimer's Disease, and the Journal of Neurochemistry, have highlighted the potential of lithium as a new treatment strategy for Alzheimer's disease, emphasizing the need for further clinical trials to establish safety, efficacy, and optimal dosing in humans.
